

# SOHM, Inc. Announces Fourth Quarter and Fiscal Year 2011 Operating and Financial Results



## Company meets and exceeds its own financial targets for the year 2011 and reports 72% revenue growth, 44% improvement in bottom line results

BUENA PARK, CA—(Marketwire – February 8, 2012) – SOHM, Inc. (PINKSHEETS: [SHMN](#)), a generic pharmaceuticals, nutraceutical and dermatology company that manufactures and markets generic drugs covering all major treatment categories, today announced its financial result for 4th quarter and fiscal year 2011.

Revenues for the fourth quarter, period ending December 31, 2011 were \$530,989, an increase of \$391,726, or a 381% increase, as compared to the same period last year. Net loss for the quarter was \$52,220, as compared to a net loss of \$280,886 for the same period last year. The bottom line results improved 252% as compared to the same period last year.

Revenues for the full year 2011 were \$1,349,341, an increase of \$567,666, or a 72% increase as compared to 2010 revenues. Net loss for fiscal year 2011 was \$548,990, as compared to a net loss of \$980,457 for fiscal year 2010. The bottom line results for 2011 improved 44% as compared to fiscal year 2010.

Mr. Shailesh Shah, CEO of SOHM Inc., stated, “We continue to make significant improvements in our top and bottom line results and believe our infrastructure, combined with our sales and marketing plans will continue to provide very good results. Last year we made strategic changes in our systems, including distribution channels and became very aggressive towards new product and new market launches, all of which provided our customers with better service and allowed us to streamline operations and control expenses.”

“We are focusing our business plan on profitability by continuing to expand operations and partnerships, but ensuring that our expenses are in line with gross profit margins,” concluded Mr. Shah.

About SOHM, Inc.

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia.  
[www.sohm.com](http://www.sohm.com)

Safe Harbor Statement:

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:

Andrew Barwicki

SOHM, Inc.

Investor Relations

(714) 522-6700